Pulse Biosciences (NASDAQ:PLSE) Hits New 52-Week High – Should You Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares hit a new 52-week high during trading on Friday . The stock traded as high as $27.98 and last traded at $27.10, with a volume of 1216047 shares trading hands. The stock had previously closed at $23.96.

Wall Street Analysts Forecast Growth

PLSE has been the subject of several research analyst reports. Oppenheimer restated an “outperform” rating and set a $30.00 price objective on shares of Pulse Biosciences in a research report on Friday, February 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Tuesday, April 21st. Mizuho set a $30.00 target price on shares of Pulse Biosciences in a research note on Friday, February 6th. Finally, Wall Street Zen raised shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pulse Biosciences currently has an average rating of “Hold” and a consensus target price of $30.00.

Pulse Biosciences Stock Up 13.1%

The company has a market cap of $1.85 billion, a P/E ratio of -24.64 and a beta of 1.63. The firm’s 50 day moving average is $21.22 and its two-hundred day moving average is $17.75.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. As a group, research analysts forecast that Pulse Biosciences, Inc will post -1.29 EPS for the current fiscal year.

Insider Buying and Selling

In other Pulse Biosciences news, CEO Paul A. Laviolette acquired 15,000 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The shares were bought at an average price of $19.69 per share, with a total value of $295,350.00. Following the completion of the purchase, the chief executive officer directly owned 15,000 shares in the company, valued at $295,350. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Robert W. Duggan acquired 660,233 shares of Pulse Biosciences stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $19.69 per share, for a total transaction of $12,999,987.77. Following the purchase, the director owned 48,211,433 shares of the company’s stock, valued at $949,283,115.77. The trade was a 1.39% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 74.60% of the stock is currently owned by insiders.

Institutional Trading of Pulse Biosciences

Institutional investors have recently bought and sold shares of the company. Argo Wealth Advisory LLC bought a new stake in Pulse Biosciences during the fourth quarter valued at $387,000. Tudor Investment Corp ET AL bought a new stake in Pulse Biosciences during the fourth quarter valued at $382,000. Barclays PLC boosted its position in Pulse Biosciences by 8.5% during the fourth quarter. Barclays PLC now owns 27,652 shares of the company’s stock valued at $380,000 after acquiring an additional 2,164 shares during the last quarter. Alliancebernstein L.P. grew its stake in Pulse Biosciences by 6.7% during the third quarter. Alliancebernstein L.P. now owns 20,620 shares of the company’s stock worth $365,000 after purchasing an additional 1,300 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Pulse Biosciences during the first quarter worth approximately $323,000. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.